{
  "zip": "CF35 5HY",
  "sector": "Healthcare",
  "fullTimeEmployees": 62,
  "longBusinessSummary": "ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.",
  "city": "Pencoed",
  "phone": "44 20 3819 8400",
  "country": "United Kingdom",
  "companyOfficers": [],
  "website": "http://www.reneuron.com",
  "maxAge": 1,
  "address1": "Pencoed Business Park",
  "industry": "Biotechnology",
  "previousClose": 1.68,
  "regularMarketOpen": 1.68,
  "twoHundredDayAverage": 1.3680576,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 1.68,
  "navPrice": null,
  "averageDailyVolume10Day": 662,
  "totalAssets": null,
  "regularMarketPreviousClose": 1.68,
  "fiftyDayAverage": 1.1875757,
  "trailingAnnualDividendRate": null,
  "open": 1.68,
  "averageVolume10days": 662,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 0.779877,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 1.68,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 582,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 88439736,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 606,
  "priceToSalesTrailing12Months": null,
  "dayLow": 1.68,
  "ask": 0,
  "ytdReturn": null,
  "askSize": 0,
  "volume": 582,
  "fiftyTwoWeekHigh": 2.32,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 0.95,
  "bid": 0,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": 0,
  "dayHigh": 1.68,
  "exchange": "PNK",
  "shortName": "RENEURON GROUP",
  "longName": "ReNeuron Group plc",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "RNUGF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_125064",
  "uuid": "b24ecaa2-62b1-39f7-a7b3-57f86cc93de6",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": 0,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 56846700,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": 1.333,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1585612800,
  "heldPercentInstitutions": 0.34373,
  "netIncomeToCommon": null,
  "trailingEps": -0.559,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": 1.2603151,
  "heldPercentInsiders": 0.17499,
  "nextFiscalYearEnd": 1648684800,
  "mostRecentQuarter": 1601424000,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 28310456,
  "enterpriseValue": 53548864,
  "threeYearAverageReturn": null,
  "lastSplitDate": 1516752000,
  "lastSplitFactor": "1:100",
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 1.68,
  "logo_url": "https://logo.clearbit.com/reneuron.com"
}